Novartis ESMO Event Presentation
Pluvicto showed a clinically meaningful and highly statistically
significant rPFS benefit in taxane-naive patients with PSMA+ mCRPC
Primary¹ HR: 0.41 (95% CI: 0.29, 0.56); p < 0.0001
Updated HR: 0.43 (95% CI: 0.33, 0.54); p < 0.0001 (nominal)
88
100
Event-free probability (%)
80
60
60
40
40
20
20
177Lu-PSMA-617
ARPI change
0
T
0
2
4
6
8
10 12 14 16 18
Time from randomization (months)
Number of patients still at risk
T
-0
20
22
234
216
174
234
197
126
150 125
79
25
65
82
36
64
21
45
12
20
10
2
0
8
4
1
0
177Lu-PSMA-617
(n = 234)
Events, n
115 (49.1%)
ARPI change
(n = 234)
168 (71.8%)
Median rPFS
(95% CI)
12.0 months
(9.3, 14.4)
5.6 months
(4.2, 6.0)
1. Primary rPFS analysis based on centrally confirmed rPFS events with Oct. 2022 data cutoff. 2. Updated rPFS analysis (at time of 2nd interim OS analysis) based on Jun. 2023 data cutoff.
15 NOVARTIS ESMO EVENT | OCTOBER 24, 2023 | INVESTOR PRESENTATION
NOVARTIS | Reimagining MedicineView entire presentation